New targeted pill takes aim at Hard-to-Treat cancers
NCT ID NCT07383506
First seen Jun 25, 2026 · Last updated Jul 01, 2026 · Updated 2 times
Summary
This early-stage trial tests a daily oral drug called CGT6297 in 90 adults with advanced solid tumors that have a specific mutation in the PIK3CA gene. The study has two parts: first, finding a safe dose, and then looking for signs that the drug shrinks tumors. It focuses on people with endometrial cancer or certain types of breast cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CGT6297 (a daily oral pill that targets a specific cancer-driving mutation)
What this could lead to
If successful, this could point toward a new treatment option for people with advanced cancers that have a PIK3CA mutation, especially endometrial and breast cancers.
What could go wrong
This is a very early Phase 1 trial with only 90 participants, so the drug may not prove safe or effective. Side effects are unknown, and many early cancer drugs fail to advance.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
HonorHealth Research Institute
RECRUITINGScottsdale, Arizona, 85258, United States
-
NEXT Austin
RECRUITINGAustin, Texas, 78758, United States
-
NEXT Virginia
RECRUITINGFairfax, Virginia, 22031, United States
-
Washington University School of Medicine - Siteman Cancer Center
RECRUITINGSt Louis, Missouri, 63110, United States